Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome

Date
2018-11-08
Language
American English
Embargo Lift Date
Committee Members
Degree
Degree Year
Department
Grantor
Journal Title
Journal ISSN
Volume Title
Found At
BMJ
Abstract

Hydralazine, a vasodilator, is commonly used as an adjunctive treatment for moderate to severe hypertension, heart failure and hypertensive emergencies in pregnancy. Hydralazine-induced lupus was first described in 1953. Clinical presentation ranges from arthralgia, myalgia, petechiae, or rash to single or multiorgan involvement. An occurrence of systemic vasculitis is a rare complication. When presented as the pulmonary-renal syndrome, it could have a rapidly progressive course which can be fatal. Here, we describe a case of hydralazine-associated rapidly progressive glomerulonephritis and pulmonary haemorrhage. We use this case to review the current literature and discuss and highlight the importance of a high degree of clinical acumen, early diagnosis and prompt treatment for better clinical outcomes.

Description
item.page.description.tableofcontents
item.page.relation.haspart
Cite As
Aeddula, N. R., Pathireddy, S., Ansari, A., & Juran, P. J. (2018). Hydralazine-associated antineutrophil cytoplasmic antibody vasculitis with pulmonary-renal syndrome. BMJ case reports, 2018, bcr2018227161. doi:10.1136/bcr-2018-227161
ISSN
Publisher
Series/Report
Sponsorship
Major
Extent
Identifier
Relation
Journal
BMJ Case Reports
Source
PMC
Alternative Title
Type
Article
Number
Volume
Conference Dates
Conference Host
Conference Location
Conference Name
Conference Panel
Conference Secretariat Location
Version
Full Text Available at
This item is under embargo {{howLong}}